Defunct Company
Total Trials
20
As Lead Sponsor
19
As Collaborator
1
Total Enrollment
5,139
NCT00028353
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
Phase: Phase 2
Role: Lead Sponsor
Start: Apr 30, 2001
Completion: Jul 31, 2003
NCT00129142
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Phase: Phase 3
Start: Oct 31, 2003
Completion: Nov 30, 2007
NCT00106691
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Start: Jan 31, 2005
Completion: Feb 28, 2010
NCT00467844
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
Start: May 31, 2007
Completion: Sep 30, 2008
NCT01214291
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Start: Mar 31, 2011
Completion: Sep 30, 2011
NCT01326312
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
Start: Jun 30, 2011
Completion: Dec 31, 2012
NCT01355484
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Start: Jul 31, 2011
Completion: Jun 30, 2014
NCT01355497
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
NCT01393119
Phase II, Dose Finding Study of GTx-758
Start: Aug 31, 2011
NCT01420861
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
Start: Sep 30, 2011
NCT01615120
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Start: Aug 14, 2012
Completion: Nov 9, 2016
NCT01616758
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Start: Apr 30, 2013
Completion: Mar 31, 2016
NCT02368691
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Start: Jun 30, 2015
Completion: Sep 22, 2017
NCT02463032
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
Start: Aug 31, 2015
Completion: Mar 31, 2019
NCT02658448
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
Start: Jan 31, 2016
Completion: Jun 30, 2018
NCT02746328
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
Start: Apr 30, 2016
Completion: Feb 28, 2018
NCT03264651
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
Phase: Phase 1
Role: Collaborator
Start: Feb 1, 2017
Completion: Mar 21, 2018
NCT03241342
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
Start: Aug 21, 2017
Completion: Sep 21, 2018
NCT03508648
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence
Start: May 28, 2018
NCT03566290
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence
Start: Jun 28, 2018